Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Germany

In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in Germany. Topics include:Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapyResults from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapyWhen to consider first-line treatment with immune checkpoint inhibitor monotherapyUtility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapyPresenters:Georgios Gakis, MD  Professor of Urology, Staff UrologistUniversity Hospital of Würzburg  Würzburg, GermanyMario Wolfgang Kramer, MD, PhD  Consultant UrologistVice Director, UrologyUniversity Hospital Schlewig-Holstein Campus LübeckLübeck, GermanyContent based on an online IME program supported by an educational grant from Pfizer and EMD Serono, Inc.Link to full program, including associated downloadable slidesets and on-demand webcast:https://bit.ly/3kJC5SL

There are no comments yet.

Please log in to write the first comment.